UltraGreen.ai’s bold market debut has raised pressing questions among investors, analysts, and observers alike. Behind its futuristic branding, critics argue the company is fundamentally a single-product trader attempting to repackage itself with “AI” appeal.
## 1. The “AI-Washing” Problem
Despite the “.ai” appended to its name, the company’s business model remains tied almost entirely to a generic pharmaceutical dye.
In FY2024, ICG accounted for **94.2%** of total revenue — a hallmark of over-concentration.
The touted “AI platform” is minimally commercial, with near-zero revenue contribution. This has led many to liken the strategy to the **dot-com era**, where companies added buzzwords to inflate valuation multiples.
## 2. more info Supply Chain Fragility
UltraGreen relies fully on external manufacturing. Instead, it depends on single-source suppliers—with its key active ingredient currently sourced primarily from **one supplier**.
This creates:
- Single-point failure risk
- Little bargaining power
- Operational vulnerability
A disruption in 2024 already caused months-long bottlenecks.
Critics argue that one factory incident could temporarily wipe out inventory.
## 3. Deteriorating Profitability
UltraGreen’s recent financials show several stress indicators:
- Net margins fell from **47.7%** → **36.6%**
- FX losses totaled **US$7.0M** in 1H2025
- The IPO price implies an **82.3% dilution** relative to NAV
These trends point toward margin compression and currency exposure problems.
## 4. Regulatory Concerns
The prospectus discloses:
- A **“major deficiency”** flagged by Irish regulators (HPRA)
- Liability surrounding **off-label usage**
- U.S. market restrictions due to **competitor exclusivity** until 2026
Such issues highlight compliance vulnerability.
## 5. The Listing Venue Questions
Industry commentary suggests the Singapore Exchange (SGX-ST) faces:
- Concerns about technical expertise
- A risk-averse culture
Critics argue this environment may enable companies to slip through with optimistic narratives despite financial red flags.
## 6. Ownership Concerns
Post-IPO, the Renew Group retains **~61.9%** control.
This means:
- Minority shareholders have limited influence
- Complex reporting lines persist due to overlapping leadership roles.
## 7. Risks to the Core Business
UltraGreen’s reliance on ICG faces new threats:
- Emerging **spectral imaging** technologies that don’t require injection dyes
- A recently sold PACS business, reducing proven tech revenue
- An AI platform that the prospectus admits may contain **bugs and defects**
This raises doubts about whether the company’s pivot toward AI is sustainable or merely cosmetic.
## Conclusion
UltraGreen.ai’s prospectus, corporate structure, and market positioning collectively reveal a legacy business with a modern label.
Investors should approach with careful due diligence.
This analysis is based solely on the UltraGreen.ai Limited Prospectus dated 26 Nov 2025 and is provided for informational and educational purposes only.